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      In 1967m Kanazawa University Cancer Research Institute was 
founded as the only Cancer Research Institute of the Ministry of 
Education, Culture, Sports, Science and Technology (MEXT).  In 
1997, our organization was rearranged and at the same time Center 
for the Development of Molecular-targeted Drugs was established.  
Since its establishment, our institute produced epoch-making 
achievements in basic cancer research field, such as the discovery of 
proteinase MT1-MMP, elucidation of function of chemokines and 
apoptosis.
      In 2006, Cancer Research Institute was reorganized and 2 
centers were newly established, “Cancer and Stem Cell Research 
Center” and “Molecular and Cellular Targeting Translational 
Oncology Center”, which aim discovery of the role of cancer stem 
cells in drug resistance and development of innovative diagnostic 
and therapeutic strategy, respectively.  We then discovered the 
molecular mechanism for maintenance of leukemia stem cells.  In 
2010, our Research Institute has been further reorganized to establish 
4 programs to identify mechanisms of metastasis, relapse, and drug 
resistance.  They are "Cancer and Stem Cell Research Program", 
"Cancer Microenvironment Research Program", "Cancer Molecular 
Target Exploration Program", and "Cancer Therapeutics 
Development Program".  Currently, Cancer stem cell biology, 
molecular mechanisms of drug resistance, and chronic inflammation 
and cancer are research fields that we are leading in the cancer 
research field.   
      In July 2010, our institute was authorized by the MEXT as the 
Joint Usage/Research Center on Metastasis and Drug Resistance, 
and started the Joint Usage/Research Center Program.  In Cancer 
Research Institute, researchers from a variety of fields including 
natural science, engineering, and clinical medicine have assembled 
to establish a cutting-edge research locus, to prevail over metastasis 
and drug resistance. With the authorization as the Joint Usage/ 
Research Center, all members in the Institute are endeavoring to 
widen collaboration with researchers in a wide variety of fields, to 
establish an international center of excellence on metastasis and drug 
resistance and to eventually promote research for conquering these 
conditions.
      With the publication of the 2014 Kanazawa University Cancer 
Research Institute Outline, I would like to request your continuous 
support and understanding.　
Masanobu Oshima, D.V.M., Ph.D.
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Stem cells are defined as cells that have the ability to 
perpetuate through self-renewal, and develop into mature cells of 
a particular tissue through differentiation. Appropriate controls of 
stem cell functions are critical for maintaining tissue homeostasis.
We have revealed that genes that are involved in longevity, 
including FOXO and mTOR pathways, contribute to the 
maintenance of stem cell self-renewal capacity. Thus, signaling 
pathways for control of intracellular metabolism may play a 
critical role in stem cell regulation.
Recent evidence has demonstrated that in tumors only a 
minority of cancer cells has the capacity to proliferate extensively 
and form new tumors. These tumor-initiating cells, which are 
calledcancer stem cells, are thought as a novel target for cancer 
therapy. The investigation of distinct and parallel roles in normal 
stem cells and cancer stem cells will contribute to the design of 
cancer therapy without damaging normal tissues.
Division of Molecular Genetics
遺伝子・染色体構築研究分野
8
Fig.1 ■ Nutrient sensor signals
図１ ■ 栄養センサーシグナル
Fig.2 ■ mTOR and FOXO pathways in quiescent hematopoietic 
stem cells
図２ ■ 静止期造血幹細胞におけるmTORおよびFOXO経路
Fig.3 ■ FOXOactivation for drug-resistance of leukemia stem cells
図３ ■ 治療耐性白血病幹細胞におけるFOXO活性化
Fig.4 ■ mTOR complex in leukemia stem cells
図４ ■ 白血病幹細胞におけるmTOR複合体機能
Aims and Major projects
Genetic alterations in epithelial cells and construction of 
tumor microenvironment are important for tumor promotion 
and malignant progression.  Our aim is to elucidate the role 
of inflammatory microenvironment in tumorigenesis through 
the following projects 
【Macrophage-induced Wnt promotion】 Macrophage niche 
is important for tumor promotion.  We found that TNF 
expressed by macrophages promotes Wnt signaling in gastric 
tumor epithelial cells, which contributes to tumorigenicity of 
cancer cells  (Oguma K, et al, EMBO J, 2008).  
【Innate immunity and microenvironment generation】 Gan 
mice develop inflammation-associated gastric tumors by 
activation of Wnt and PGE2 pathways.  Notably, gastric 
tumorigenesis was significantly  suppressed in germfree Gan 
mice, suggesting the role of innate immune response in gastric 
tumorigenesis (Oshima H, et al, Gastroenterology, 2011).
【Inflammation and microRNA】 Expression profile of 
microRNAs in Gan mouse tumors was examined.  We found 
that tumor suppressor microRNA, miR-7, is downregulated by 
inflammation-dependent mechanism, which contributes to 
gastric tumorigenesis (Kong D, et al, Oncogene, 2012).
【TNF-dependent tumorigenesis and stemness】 Disruption 
of Tnf gene in Gan mice caused significant suppression of 
gastric tumorigenesis.  One of TNF-dependent factor, Noxo1, 
is also induced in normal stem cells, and plays a role in 






図２ ■ 胃がん組織への顕著なマクロファージ浸潤  
Tnf-/- Gan マウスでは胃がん発生が顕著に抑制されるが、Tnf 野生型GFPマウス
から骨髄移植すると、胃がんが発生し（左）、GFP陽性細胞浸潤が観察される（右）。
この結果は、マクロファージ由来TNFの重要性を示唆している。
Gastric tumorigenesis was significantly suppressed in Tnf-/- Gan mice. Bone marrow 
transplantation to Tnf-/- Gan mice from GFP transgenic mice resulted in gastric tumor 
development, indicating the role of bone marrow-derived macrophages in tumor 
promotion.
Gan マウスに GFP マウスから骨髄移植すると、胃がん組織への GFP 陽性骨髄細
胞の浸潤が見られる。その多くはマクロファージであり（左）、上皮細胞に分化する
細胞は見られない（右）。
Bone marrow transplantation to Gan mice from GFP transgenic mice revealed significant 
infiltration of bone marrow-derived cells to tumor tissues, and most of them are 
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We innovate in vitro and in vitro cancer model systems that can  
be readily analyzed by genetic and molecular biology techniques. 
This aims to find pathways critical for carcinogenesis, metastasis, 
drug resistance, and stem cell-like behaviors in cancer cells. 
Below are ongoing projects in our laboratory.
1 ) The RB tumor suppressor gene product has been implicated in 
control of cell cycle and terminal differentiation. However, we 
propose pRB plays many more roles during tumor progression 
beyond such functions.We focus onpRB functions in 
chromatin instability, DNA damage response, cellular 
senescence, mevalonate pathway, lipid metabolism, 
mitochondrial function, chromatin remodeling and stem cell- 
like behaviors in cancer cells.
2 ) Analysis of oncogenic signals that induce malignant behaviors 
in cancer cells through metabolic reprogramming.
3 ) Development of in vitro & in vitro cancer stem cell models in 
an aim to develop novel drugs or chemicals that specifically 












Cellular signals merged on the modulation of pRB functions, 
and effectors of pRB. This at least partially explains multi-





Stem cell-like cells appeared in cancers induced by the 
combinational suppression of tumor suppressor genes 
including Rb.





















     Although the discovery of the tyrosine kinase inhibitors (TKI) 
have significantly improved the prognosis of chronic myeloid 
leukemia (CML) patients, a complete cure is not possible due to 
the existence of a rare population of CML stem cells known to be 
resistant to TKI therapy. We have recently reported that Forkhead 
transcription factor (FOXO) is essential for the TKI-resistance of 
CML stem cells (Fig. 1). Furthermore, TGF-β originate from the 
microenvironment regulates FOXO activity in CML stem cells. 
Importantly, a combined administration of TGF-β inhibitor and 
TKI leads to reduction of CML stem cells in vivo. Our results 
demonstrate a critical role for the TGF-β-FOXO pathway in the 
maintenance of TKI-resistant CML stem cells (Fig. 2). 
     The purpose of our current research is to clarify the molecular 
mechanisms governing TKI-resistance of CML stem cells via 
TGF- β -FOXO signaling pathway. The long-term outcome of our 
investigation will hopefully be the development of novel agents 
that can specifically suppress the effects of these TGF-β-FOXO 
signaling pathway, and thereby provide a novel avenue for 
curative CML patient therapy.
がん幹細胞探索プロジェクト
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Fig.1 ■ FOXO plays an essential role for the tyrosine kinase 
inhibitor (TKI) resistance of CML stem cells
Mice transplanted with wild-type (Foxo3a+/+) or Foxo3a-deficient (Foxo3a-/-) CML 
stem cells received TKI. FOXO deficiency promoted the survival of CML-affected 
mice after administration of TKI, indicating that FOXO is responsible for the 
maintenance of TKI-resistant CML stem cells.
Fig.2 ■ TGF-β-FOXO signaling pathway maintains TKI-
resistant CML stem cells
We have recently reported that FOXO is crucial for the TKI resistance of CML stem 
cells. Furthermore, TGF-β originate from the microenvironment regulates FOXO 
activity in CML stem cells. The goal of our research is development of novel agents 
that can specifically suppress the effects of these TGF-β-FOXO signaling pathway, 
and thereby provide a novel avenue for curative CML patient therapy.
図２ ■ TGF-β-FOXOシグナルによるCML幹細胞のTKI抵
抗性制御メカニズム
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を発見し MT1-MMP と命名した (Nature，1994)。MT1- 
MMP は細胞浸潤のみならず増殖・運動などの調節にも重
要な役割を果たしているとのデーターが蓄積しつつある。
Aim and Projects on going
    Accumulation of mutation in ocogenes and tumor suppressor 
genes in normal cells results in malignant tumors. Malignant 
tumors invade into tissues and finally metastasize to distant 
organs. The goal of our project is to elucidate the molecular 
mechanism of tumor metastasis and develop diagnostic and 
therapeutic application.
  Tumor invasion into tissue requires degradation of tissue 
basement membrane. We discovered a protease which is the key 
enzyme for tumor metastasis, and named it as MT1-MMP 
(Nature, 1994). Accumulating evidences indicate that MT1-MMP 
plays important roles in not only tumor invasion but also 









Fig. 1 ■ Induction of MT1-MMP and Invasive Growth by Ocnogenic 
Transformation of Normal Epithelial Cells
Normal epithelial MDCK cells were transformed with oncogne (erbB2), and showed 
tumor phenotype including MT1-MMP expression. Normal cells grow to form cysts in 
collagen gel, but transformed cells which express MT1-MMP show invasive growth. 
Tumor invasive growth is suppressed by the addition of MMP inhibitor BB94. Normal 








Fig. 2 ■ Cell Migration and MT1-MMP
HT1080 cells were cultured on collagen, which express MT1-MMP, and were stained 
for paxillin to visualize focal adhesion and actin. Addition of MT1-MMP inhibitor BB94 
altered the localization of focal adhesion, reduced cell polarity and suppressed cell 
migration. MT1-MMP enhances motility signal by stimulating turnover of focal 
adhesion.
Division of Molecular Virology and Oncology
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Aims, Ongoing Projects, and Recent Achievements
     Inflammatory responses occur upon tissue injuries, to reduce 
tissue damage.  If inflammatory responses are exaggerated and 
prolonged as observed in chronic infection with Helicobacter 
pylorii, tissue injuries continue, leading sometimes to 
carcinogenesis.
    By interacting with tumor cells, stroma cells and leukocytes 
can produce variouse bioactive subustances including chemokies. 
The produced molecules can affect tumor progression and 
metastasis.We are elucidating the interaction between tumor cells 
and stroma cells and obtained the following results recently.
1) By using mice deficient in chemokine-related genes, we are 
showing that chemokines can contribute to tumor development 
and progression by exerting various activities.
2) We revealed that the expression of a serine/threonine kinase, 
Pim-3, was aberrantly enhanced in malignant lesions of liver 
and pancreas.  Moreover, aberrantly expressed Pim-3 can 
inactivate a proapoptotic molecule, Bad by phosphorylating its 
serine residue, and eventually prevent apoptosis of tumor cells. 































Fig. 1 ■ Roles of chemokines in tumor progression and 
metastasis processes
Various chemokines contributes to progression and metastasis through the 
following functions.
a . Regulation of immune cell trafficking
b . Induction of neovascularization
c . Enhancement of tumor cell motility






Fig. 2 ■ Aberrant expression of a serine / threonine kinase, 
Pim-3 in malignant lesions
Pim-3, aberrantly expressed in various malignant lesions, inactivates a pro-
apoptotic molecule, Bad by phosphorylating its serine residue, and eventually 
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Fig. 2 ■ Cell Migration and MT1-MMP
HT1080 cells were cultured on collagen, which express MT1-MMP, and were stained 
for paxillin to visualize focal adhesion and actin. Addition of MT1-MMP inhibitor BB94 
altered the localization of focal adhesion, reduced cell polarity and suppressed cell 
migration. MT1-MMP enhances motility signal by stimulating turnover of focal 
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     Each cell composing our body is programmed to kill itself when 
necessary. Apoptosis is a common type of such programmed cell 
death. To prevent oncogenesis, cells often die by apoptosis when their 
genes are severely damaged by radiation, oxidative stress, etc. Many 
chemotherapeutic agents also induce apoptosis in tumor cells. 
     Meanwhile, recently, it was revealed that dying and/or dead cells 
release a variety of inflammatory factors. Because many cells were 
killed in tumors by hypoxia, anti-tumor immune responses, or 
therapeutic treatments, it can be assumed that dead cell-derived 
inflammatory factors contribute to the generation of inflammatory 
environment of tumor tissues, and hence play an important role in the 
tumor development. In addition, several novel modes of programmed 
cell death that are clearly distinct from apoptosis have been 
discovered.
     In our laboratory, we are studying the molecular mechanisms of 
induction and execution of programmed cell death, and dead 
cell-derived inflammatory factors, aiming to find new strategy to 
induce programmed death of tumor cells that is greatly effective for 
tumor eradication.




Fig. 1 ■ Therapeutic effect of an anti-FasL antibody
in an animal model of chronic hepatitis. 
図２ ■ 









Pyroptosis is a non-apoptotic inflammatory programmed cell death. We established a model 
tumor cell line (CLC12N2) by introducing an artificial protein that induce pyroptosis in response 
to muramyl dipeptide (MDP) treatment into the COLO205 human colon cancer cell line. 
CLC12N2 (but not COLO205) tumor implant in nude mice were rejected when pyroptosis was 






We have demonstrated that a neutralizing antibody against Fas ligand 
(FasL), an apoptosis-inducing protein, has therapeutic potential in 
animal models of inflammatory diseases including hepatitis. 
Furthermore, this antibody prevented hepatic cancer development in 
an animal model of chronic hepatitis. We also discovered that FasL 







































     Hepatocyte growth factor (HGF) was originally discovered as 
a mitogenic protein for mature hepatocytes. HGF exerts various 
biological activities, including cell proliferation, 3-D 
morphogenesis, migration, and anti-apoptosis in diverse biological 
processes. The receptor for HGF is Met tyrosine kinase. HGF 
plays critical roles in dynamic morphogenesis and regeneration of 
various tissues such as the liver. In cancer tissues, however, 
aberrant activation of the Met/HGF receptor is tightly associated 
with malignant progression of cancer, i.e., 3-D invasion, 
metastasis, angiogenesis, and drug resistance. Thus HGF-Met 
system is emerging hot target in the molecular targeted therapy of 
cancer. Our research projects include 1) regulation of tumor 
invasion-metastasis via HGF-Met pathway, 2) aberrant Met 
activation and drug resistance in cancer cells, 3) discovery of 
HGF-Met inhibitory molecules (NK4 and small synthetic) and 
anti-cancer approach with HGF-Met inhibitors, and 4) 
significance of suppressive mechanisms for the HGF-dependent 
Met activation in 3-D epithelial morphogenesis and tissue 
regeneration. HGF-Met system makes a way for dynamic 3-D 
reconstruction of tissues via epithelial-mesenchymal interactions 
for regeneration of wounded tissues, whereas it is utilized for 
acquisition of malignancy of cancers. The simile that "cancer is 
never-healing wound" seems pertinent from the aspect of HGF- 
Met. 
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Fig. 2 ■ 3-D morphogenesis and inhibition of tumor invasion
HGF induces 3-D epithelial morphogenesis/tubulogenesis (upper). 
The response to HGF depends on 3-D position of cells. Mechanism 
for 3-D position-dependent Met activation leads to understanding of 
morphogenesis and tumor invasion. Our research includes drug 
discovery targeting HGF-Met. An inhibitory molecule for HGF-Met 
inhibits tumor invasion (lower). HGF-Met inhibitors are expected to 
suppress cancer invasion, metastasis, and drug resistance.
Fig. 1 ■ Biological functions of HGF in regeneration, 
3-D morphogenesis, and tumor invasion-
metastasis
HGF exerts biological actions through the Met, and plays roles in 
tissue regeneration and 3-D morphogenesis. In cancer tissues, HGF 
plays a definitive role in invasion, metastasis, and drug resistance. 
Met activation by HGF become therapeutics for treatment of 
diseases, while inhibition of HGF-Met become anti-cancer 
therapeutics, leading to inhibition of metastasis and drug resistance.
     Each cell composing our body is programmed to kill itself when 
necessary. Apoptosis is a common type of such programmed cell 
death. To prevent oncogenesis, cells often die by apoptosis when their 
genes are severely damaged by radiation, oxidative stress, etc. Many 
chemotherapeutic agents also induce apoptosis in tumor cells. 
     Meanwhile, recently, it was revealed that dying and/or dead cells 
release a variety of inflammatory factors. Because many cells were 
killed in tumors by hypoxia, anti-tumor immune responses, or 
therapeutic treatments, it can be assumed that dead cell-derived 
inflammatory factors contribute to the generation of inflammatory 
environment of tumor tissues, and hence play an important role in the 
tumor development. In addition, several novel modes of programmed 
cell death that are clearly distinct from apoptosis have been 
discovered.
     In our laboratory, we are studying the molecular mechanisms of 
induction and execution of programmed cell death, and dead 
cell-derived inflammatory factors, aiming to find new strategy to 
induce programmed death of tumor cells that is greatly effective for 
tumor eradication.




Fig. 1 ■ Therapeutic effect of an anti-FasL antibody
in an animal model of chronic hepatitis. 
図２ ■ 









Pyroptosis is a non-apoptotic inflammatory programmed cell death. We established a model 
tumor cell line (CLC12N2) by introducing an artificial protein that induce pyroptosis in response 
to muramyl dipeptide (MDP) treatment into the COLO205 human colon cancer cell line. 
CLC12N2 (but not COLO205) tumor implant in nude mice were rejected when pyroptosis was 
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     Our major research interest is to elucidate the molecular 
mechanisms regulating cancer cells, stem cells and cancer stem 
cells. Our team has two important research directions: One is to 
clarify the basic principles underlying biology and the other is to 
apply the knowledge extracted from the basic principles to 
translational medicine. In order to achieve the goal, we take 
challenging approaches of molecular biology and systems biology, 
in addition to conventional methods of molecular biology. 
1)  Molecular mechanisms of cancer initiation, progression and 
metastasis: breast cancer stem cells as key players
By analyzing the mouse cancer model or primary cancer cells 
derived from human specimens, we attempt to identify novel  
molecular targets and biomarkers for cancer.
2)  Identification of new biomarkers and molecular targets of lung 
cancers by systems biology approach
Our hypothesis is that elucidation of the molecular 
mechanisms of addiction of lung epithelial cells to EGF RTK 
signaling leads us to identify new biomarkers and molecular 
targets of lung cancer. Our approach would certainly advance 
personalized medicine in the near future.
3) Signal transduction mechanisms through receptor tyrosine 
kinases(RTKs)for tumorigenesis and stem cell maintenance
Fibroblast growth factor (FGF) and epidermal growth factor 
(EGF) RTKs play major roles for a variety of physiological 
and pathological aspects of biology, including stem cell 
biology, and cancer biology. We focus on FRS2 family of 
adaptor/scaffolding docking proteins, as key intracellular 
signal regulators of these RTKs.
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Activation of heregulin-phosphatidyl inositol (PI)-3 kinase 
pathway induces various cytokines, growth factors and 






The 139 key genes involved in EGF signaling accurately predict 





・MAPKカスケードの in vivo における機能の解明
・MAPKカスケードの特異性を保持する分子機構の解明
を目指して研究を進めている。
     Abnormal activation of intracellular signaling pathways often 
leads to tumors.  The goal of our project is to elucidate the 
functions of MAP kinase (MAPK) cascades in vivo, which are 
major intracellular signaling pathways, and the molecular 
mechanisms of how the specificity of MAPK cascades is 
maintained.
Division of Molecular Cell Signaling
シグナル伝達研究分野
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Fig. 1 ■ Function of MAPK cascade in vivo, and Formation 
of Multikinase Complex by Scaffold Protein
 era stnenopmoc rojam hcihw ni ,sedacsac KPAM taht etacidni seiduts tneceR
MAPK, MAPK kinase (MAPKK), and MAPKK kinase (MAPKKK), play 
important roles in cell proliferation, differentiation, and apoptosis.  Scaffold 











Fig. 2 ■ JLP ablation reduces ultraviolet B (UVB)-induced 
apoptosis in mice.
The ultraviolet B (UVB) component of sunlight can cause severe damage to skin 
cells and even induce skin cancer. We investigated the function of the scaffold 
protein JLP in UVB-induced apoptosis in the skin by analyzing Jlp-deficient 
mice. Our results suggest that JLP plays an important role in this apoptosis by 
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Research Direction and Activities
     The mission of the division centers on laboratory and clinical 
research to develop the novel strategies and modalities for 
diagnosis and treatment of the gastrointestinal and refractory 
cancers. Research projects are based on molecular and cellular 
characteristics of individual tumor types that are relevant to 
invasive and metastatic potential, recurrence and outcome. Our 
current efforts are focused on:
1)  Molecular mechanism underlying oncogenic signaling 
pathways
(1) Deregulated Wnt/β-catenin signaling
(2) Glycogen synthase kinase 3β (GSK3β)-mediated signaling
2)  Molecular basis of gastrointestinal and refractory cancers for 
clinical translation 
3)  Establishment of tissue material resources of human 
gastrointestinal cancer
      We are intending to translate as much the achievements created 
from these studies as possible to the fields responsible for 





Glycogen synthase kinase 3β (GSK3β) supports and promotes 
tumor cells' survival and proliferation, and protects them from 
apoptosis in cancers developed in the major digestive organs, the 





RNA trans-factor CRD-BP is a previously unrecognized 
transcription target of β-catenin/Tcf complex, and stabilizes 
mRNA of β-TrCP1 (β-transducin repeats-containing protein 1), 
IкBα and c-Myc. CRD-BP is a novel cancer target that integrates 
multiple oncogenic signaling pathways (Nature June 15, 2006; 
Cancer Res Nov 15, 2009).
腫瘍制御研究分野


























     A detailed knowledge of the genes and signaling pathways 
mutated in cancer will be required to develop the novel target- 
based cancer therapeutics. However, the heterogeneity and 
complexity of genomic alterations in most human cancers hamper 
straightforward identification of cancer-causing mutations. We use 
the retrovirus-infected mice as model systems for identifying new 
cancer genes efficiently. Retroviruses induce tumors through 
activation of proto-oncogenes or inactivation of tumor suppressor 
genes as a consequence of retroviral integrations into host 
genome. Thus the viral integration sites provide powerful genetic 
tags for cancer gene identification. We are exploring the novel 
molecular targets for cancer treatment based on functional 
characterization of the cancer genes isolated by high-throughput 
screens using retroviral insertional mutagenesis. Once these genes 
are identified, we use gene knockout and transgenic mice to 
understand how these genes function in tumorigenesis, and to 
develop new animal models for human cancer. Our current 
projects are as follows.
1) Identification of novel cancer genes using retroviral insertional 
mutagenesis in mice
2) Involvement of histone methyltransferases and demethylases 
in the initiation and progression of cancer
3) The role of three families of enzymes in DNA demethylation 
pathway on cancer development
4) Functional analysis of the novel cancer genes using conditional 
knockout mice








Bloom syndrome is a recessive genetic disorder associated with genomic instability that causes 
affected people to be prone to cancer. The mutant mice for Bloom (Blm) gene showed increased 
rate of sister chromatid exchange, somatic recombination and loss of heterozygosity. The Blm 
mutant mice enhance our ability to identify tumor suppressor genes, because the tumors derived 
from virus-infected Blm mice are more likely to carry viral integrations in both alleles of tumor 
suppressor genes through their genomic instability. 
Histone modifications have important roles in regulating gene expression and genome function by 
establishing global chromatin environments. The methylation of four lysine (K) residues on the 
tail of histone H3 (K4, K9, K27 and K36) is regulated by a large number of histone 
methyltransferases and demethylases. Among them, most of the genes (shown in red) were 














Efficient isolation of candidate tumor suppressor genes using
retrovirus-infected Bloom syndrome model mice
Most of the genes that encode histone methyltransferases and demethylases
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Cancer Therapeutics Development Program
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     Lung cancer is the leading cause of malignancy-related death 
in Japan. High mortality of lung cancer is due to low susceptibility 
to anti-cancer drugs and high metastatic potential.
    We recently discovered a novel mechanism by which 
hepatpcyte growth factor (HGF) induces resistance to gefitinib 
and erlotinib in lung cancer. We also reported that histone 
deacethylase (HDAC) inhibitors overcome targeted drug-
resistance due to BIM polymorphism, which is specifically found 
in Asian. We are now conducting the clinical trials to overcome 
resistance caused by these mechanisms.
    Since clinically relevant animal models are essential for 
elucidating the molecular pathogenesis of cancer metastasis, we 
have establ ished reproducible  in  vivo imaging models  
representing multi-organ metastasis, brain metastasis, lung 
metastasis, bone metastasis, or malignant pleural effusion, using 
human lung cancer cell lines.  We are elucidating anti-metastatic 
effects of several molecular targeted drugs in these models.
     Furthermore, we established orthotopic implantation models of 
malignant pleural mesothelioma and gastric cancer. The goal of 
our translational research with these animal models is the 
establishment of novel molecular targeted therapeutics for solid 
tumors, such as malignant pleural mesothelioma, pancreatic 
cancer and gastric cancer.





Fig.1 ■ Molecular mechanism by which 
HGF induces resistance to gefitinib 




Fig.2 ■ S trategy to overcome BIM 
polymorphism-associated targeted 
drug resistance by combined use of 
HDAC inhibitors
図３ ■ 多臓器転移のin vivoイメージ
ング
  肝転移や骨転移の検出が可能
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■ 中央実験施設　Central Research Resource Branch
中央実験施設











































    The LaThetaTM CT scanner is designed for small animals 
and intended especially for the in-vivo and ex-vivo animal 
research. Its extremely sensitive detector allows working 
with low energy x-ray source, making possible longitudinal 
studies. This CT scanner has been used to monitor tumour 
growth and metastasis.
     Normal or cancer cells consist of heterogeneous cell-
populations.  The BD FACS Aria, which was purchased in 
2005, allows the isolation of defined cell subset(s) from 
heterogeneous mixtures.  Cells can be sorted according to 
size, granularity, surface markers and DNA content.  An 
advantage of using the FACS Aria is that cells can be sorted at rates up to 10,000 cells/second in a sterile environment enabling the recovered
cells to be cultured. This is also applicable to transfected cells, where onle a small proportion of the cells may express the antigen of interest. 







Central Research Resource Branch was established, so that the 
equipment is accessible by anyone and collaborative research can be 
carried out. Below is a list of the facilities.
■ 自動セルソータ （ー自動細胞解析分取装置） 　Automated Cell Sorter
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     The DNA Sequencer determines the cloned DNA's base sequence automatically, unlike the old method, it uses no radioactive substances. 
The method used here is to distinguish the base by laser from 4 varieties of fluorescence activated substances, in addition, it is also equipped 










     The confocal laser scanning microscope (Carl Zeiss LSM 
510) can set the spectrum fluorescence to arbitrary detection 
wave length  by  the  s l i t .  The  in ter ference  wi th  the  
fluorescent wave length can be suppressed to the minimum.
Therefore, this microscope resolves spectrally overlapping 
emissions under multiple staining. Ar (458/477/488/514nm) 
and the HeNe (543 • 633nm) laser are installed in this 
microscope. Many researchers are using this microscope 
frequently, since it is indispensable for current cell biology.
■ DNAシーケンサー　DNA Sequencer










     Main projects of this branch are as follows.
1) A study on the determinant of chemosensitivity to antitumor 
nucleosides in cancers (ENDO)
2) Antitumor effects of photodynamic diagnosis and therapy 
using 5-aminolevulinic acid in cancers (ENDO)
3) Molecular biology of hepatitis B viruses (KUROKI)







Fig.1 ■ Detection of disseminated MKN-45 cells in peritoneal 
cavity of nude mice by ALA-PDD
(A) Highly metastatic MKN-45-P cells were inoculated i.p. into nude 
mice. (B) 5-Aminolevulinic acid was injected i.p. and mice were 
exposed to blue LED light (405nm). (C) Disseminated cells in 








Fig.2 ■ Renal and ovarian anomalies in ADAMTS-1 null mice.
(A) Structure of the ADAMTS-1 protease. ADAMTS-1 null mice 
displayed renal anomalies, which resemble ureteropelvic junction (UPJ) 
obstruction (B). The ovulatory ability was signiﬁcantly impaired in 
ADAMTS-1 null mice (C). ADAMTS-1 null ovaries also included a 







Fig.3 ■ Infection mechanism of hepatitis B viruses.
To understand the nature of the uptake pathway for hepadnaviruses, 
we have begun the search for the host proteins that interacts to 
envelope proteins of the duck hepatitis B virus (DHBV) as a model of 
these viruses. After our ﬁnding of novel carboxypeptidase gp180, 
which is now regarded as a host receptor, recent experiments suggest 
that second host component may be required with gp180 to fully 
reconstitute viral entry.
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 Tumor Metabolism-senescence and beyond
 Daniel S.Peeper（オランダがん研究所・オランダ）
　原　　英二（がん研究会がん研究所）






















































①「ALK, ROS1 and RET fusions in lung adenocarcinomas 
from China」　Yihua Sun（復旦大学上海がん病院）
②「Involvement of histone methyl-modifying enzymes in 
cancer development identified by retroviral insertional 
mutagenesis」　鈴木　健之（金沢大学がん進展制御研究所）
③「Overexpressed CD59 in Cancer Cells: Mechanisms 
and Strategies」　Weiguo Hu（復旦大学上海がん病院）
④「Circumvention of molecular targeted drug-resistance in 
lung cancer」　矢野　聖二（金沢大学がん進展制御研究所）
⑤「Prostate Cancer in China: Epidemiology, Characteristics 
and Management」　Yao Zhu（復旦大学上海がん病院）
⑥「Expanding Roles of the CCL3 Axis in Carcinogenesis 
and Leukemogenesis Processes---Beyond Leukocyte 
Chemotaxi 」　向田　直史（金沢大学がん進展制御研究所）
５．大学院生国際交流会
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　To bus stop "Kanazawa Univ. shizenken-mae"　about 34 min.
　金沢駅東口⑥乗場→ 91 93 94 97 「金沢大学（角間）」行
　Kanazawa Station East Exit ⑥
　　　　　　　　　　→ 91 93 94 97 「Kanazawa Univ.（Kakuma）」
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　Takara-machi Campus（Division of Translational and Clinical 
Oncology,Division of Medical Oncology）
　「小立野（こだつの）」バス停下車まで　所要約20分
　To bus stop "Kodatsuno" about 20 min.
　金沢駅東口③乗場→ 11 「東部車庫」行など
　Kanazawa Station East Exit ③→ 11 「Toubusyako」etc
　金沢駅東口⑥乗場→ 13 「湯谷原・医王山」行など
　Kanazawa Station East Exit ⑥→ 13 「Yuyagahara・Iouzan」etc
　金沢駅西口⑤乗場→ 10 「東部車庫」行など
　Kanazawa Station West Exit ⑤→ 10 「Toubusyako」etc
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